The experimental Ebola treatment ZMapp, administered to several infected individuals during the ongoing epidemic, contains key components of 2 antibody mixtures (MB-003 and ZMab) whose mechanisms of action have remained unclear. Through the use of single-particle electron microscopy, Scripps Research Institute investigators and their colleagues have determined the structure of each antibody in ZMapp, as well as additional antibodies from MB-003 and ZMab cocktails from which ZMapp was derived, bound to the Ebola virus surface glycoprotein (Murin CD et al. Proc Natl Acad Sci U S A. doi:10.1073/pnas.1414164111 [published online November 17, 2014]).
Hampton T. Structural Analysis of Antibodies in Ebola Treatment. JAMA. 2015;313(1):20. doi:10.1001/jama.2014.16897